

PRESS RELEASE

Lunaphore closes a CHF 6M financing round

Lausanne, Switzerland, October 4th, 2017 - Lunaphore Technologies SA, a Swiss medtech company developing a next-generation technology for cancer tissue diagnostics, announces the closing of a second financing round of CHF 6M.

Lunaphore, a company based in Lausanne, Switzerland, was founded in 2014 with the vision of bringing the future of cancer tissue diagnostics to laboratories and hospitals. After achieving all key milestones to date, the company has closed a substantially oversubscribed CHF 6 million financing round in July. The new investors are Zühlke Ventures, Polytech Ecosystem Ventures and Occident Group, along with private investors. Existing investors, including Redalpine Venture Partners, contribute significantly. The funds pave the way for market access.

"We are glad to see the interest of new investors, as well as the strong confidence shown by our existing investors who increased their participation considerably," says Dr. Ata Tuna Ciftlik, Founder and CEO of Lunaphore. "We believe that Zühlke Ventures' engineering and industrialization expertise in similar spaces along with Polytech Ecosystem Ventures' footprint in Silicon Valley support the execution of our strategy and strengthen our international network," he adds.

Dr. Michael Sidler, General Partner at Redalpine, and Board Member at Lunaphore, states, *"We are very pleased to see that Lunaphore's strategy is well executed by the whole team. The impressive progress of the company has generated solid interest from strategic key players."* Dr. Patrick Griss, Executive Partner at Zühlke Ventures, adds *"I look forward to working with a fantastic team and to contributing to the development and market introduction of this truly innovative product".*

Lunaphore builds devices based on a cutting-edge technology that can significantly shorten the time of cancer diagnostics assays and with proven higher precision. The unprecedented speed and quality offered by the products both improve existing tumor analysis and, at the same time, enable a number of new applications. The microfluidic tissue processor technology has already been tested in collaboration with key opinion leaders, internationally, and in different laboratories and hospitals. So far, 3 clinical studies with more than 100 patient cases have been published. With

this latest investment, the company targets to get closer to the multi-billion tissue diagnostics market, and establish key partnerships in product development and commercialization.

About Lunaphore

Lunaphore Technologies SA was incorporated in April 2014 with the vision of building the next-generation tissue diagnostic platforms. The technology has proven higher accuracy and speed than standard methods in clinical trials performed with cancer patients' samples. Since its incorporation, Lunaphore has been supported by different programs and awarded numerous prizes nationally and internationally, recognizing the potential of the company and its cutting-edge technology. The company is listed among the 10 most successful Swiss start-ups.

About Redalpine Venture Partners

Redalpine Venture Partners is an early stage investor focusing on disruptive and highly scalable business models. Their aim is to help talented entrepreneurs turn their visions into reality. To foster entrepreneurial success, Redalpine provides financial backing as well as relevant know-how and a reliable network. Redalpine focuses on European Life-Science and ICT start-ups.

About Zühlke Ventures

Zühlke Venture AG, based in Zürich, Switzerland, is a venture capital arm of Zühlke Technology Group AG focusing on the financing of start-ups at an early stage and providing growth capital. As investors, Zühlke Ventures not only provide capital, but also access to a network of key people in different fields, including engineering and manufacturing, helping to bring top notch technologies to the market. Zühlke Ventures AG, based in Zürich, Switzerland, is a

About Polytech Ecosystem Ventures

Polytech Ecosystem Ventures is an early stage VC firm based in Switzerland and in Silicon Valley with a strong international focus. The team is made of seasoned investment professionals and industry experts with years of experience and an extensive industrial network. Their role is to build the bridge between Swiss and European start-ups with the US where they will be able to access new markets, ideas, people, and opportunities.

About Occident Group

Founded in 1993, Occident Group is an international, privately held investment company based in Zug. Occident Group currently holds more than 50 investments in venture capital, real estate development, investment properties and real assets. A strong forward-looking approach is key to Occident Group's investment philosophy, thus the focus with start-up companies is on promising innovations and highly motivated entrepreneurs with the drive for excellence and sustainable success. Occident Group acts as long-term investor and contributes more than just financial support.